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1078–5Introduction. The aim of this prospective observational registry was to study the outcome of symptomatic patients pre-
senting with recent TIA or minor stroke and severe carotid stenosis, submitted to early percutaneous treatment by stenting.
A secondary aim was to evaluate the biological activity of the symptomatic carotid plaques by serial serum and urinary
markers (PAPP-A, hs-CRP, MMP-2/MMP-9, IL-6/IL-8, TNF alpha, CD40L) measured by enzyme-linked immunosorbent
assay before and after treatment.
Methods. From May 2005 to June 2006, 57 patients were enrolled in this prospective registry. All patients underwent
carotid stenting using a concentric filter for cerebral protection. The procedure was performed within 24e48 hrs of the
last attack in patients with TIA (n¼ 24, 42%) and between 14 and 30 days in patients with stroke (n¼ 33, 58%).
Results. Successful stent implantation was achieved in all cases (100%). Adverse events at 1 month were 1 death (1.7%)
and 2 TIAs (3.5%). Some of the vulnerability markers, in particular those reflecting an active systemic inflammatory pro-
cess of the plaque (PAPP-A, hs-CR, and IL-6), were significantly elevated at the time of enrolment, increased after stenting
and decreased after 30 days.
Conclusion. Deferred CAS is feasible and safe in selected patients with symptomatic carotid stenosis. This preliminary
study in a limited series of patients with unstable carotid plaques revealed that endovascular treatment has a satisfactory
outcome considering the very high risk profile of the patient population. The evaluation of some biomarkers suggested an
inflammatory role in the process of an unstable carotid plaque generating an acute cerebral event.
 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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biomarkers.Introduction
The role of early carotid revascularization in symptom-
atic patients with severe carotid stenosis is still unclear.
Although the pooled analyses from the European Ca-
rotid Surgery Trial (ECST) and the North American
Symptomatic Carotid Endarterectomy Trial (NAS-
CET)1 clearly showed that the benefit from carotid end-
arterectomy (CEA) is maximal in symptomatic patients
operated on within 2 weeks of the index event, most
specialists involved in stroke care are reluctant to un-
dertake carotid revascularization immediately aftersponding author. C. Setacci, Vascular and Endovascular
y Unit, University of Siena, Viale Bracci, 53100 Siena, Italy.
address: setacci@unisi.it
884/000644+ 08 $34.00/0  2008 European Society for Vasculathe onset of stroke for fear that hemorrhagic transfor-
mation of the cerebral infarct will occur.2e7
Delaying intervention quite probably means that
patients are better selected, and this could guarantee
better early outcomes, but this delay can also result
in an interval stroke rate of 9e15%.8
The real goal of early intervention is to stop the pla-
que embolization from a vulnerable lesion at the
carotid bifurcation, which is the most common patho-
genic mechanism for cerebral ischemia from carotid
atherosclerotic disease. However, the challenge of rec-
ognizing vulnerable plaques noninvasively at early
stages, and before the onset of an acute clinical event,
still remains such.
A number of studies have demonstrated that ath-
erosclerosis is clearly an inflammatory disease andr Surgery. Published by Elsevier Ltd. All rights reserved.
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ids.9e11 These studies have also correlated different
biomarkers with cerebrovascular and cardiovascular
disease. However there are as yet no specific bio-
markers that allow accurate identification.
The aim of this prospective observational registry,
called SUBMARINE (Serum And Urinary Plaque Vul-
nerability Biomarkers Detection Before And After Ca-
rotid Stent Implantation) was to study the outcome of
symptomatic patients with recent first or recurrent
TIA or minor stroke, bearing severe carotid artery ste-
nosis and submitted to early percutaneous treatment
by stenting with cerebral protection using a single de-
vice (Accunet filter and Acculink stent e Abbott
Vascular Devices, Redwood City, CA, USA).
The primary end-point was the absence of cerebro-
vascular events at discharge.
Secondary end-points were: (a) the assessment of
death rate, combined stroke and death rate, and any
new neurological event (including TIA and any
stroke) at 30 days; (b) the evaluation of biological ac-
tivity of symptomatic carotid plaques by serial serum
and urinary markers, before and after treatment.Methods
The study was conducted at 8 centers. From May 2005
to June 2006, 57 patients (37 males, 65%; mean age
76.7 8.0 years) were enrolled in this prospective
registry.
Inclusion criteria were a recent (within 24 hours)
acute hemispheric event, including minor stroke, sin-
gle transient ischemic attack (TIA), or recurrent (‘‘cre-
scendo’’) TIA, in the vascular territory of a diseased
carotid arterywith documented ultrasonographic sten-
osis 50%. The target lesion stenosis wasmeasured by
the surgical team using the NASCET criteria.12
Minor stroke was defined as any new neurological
deficit that persisted for >24 hours, associated with
a modified Rankin13 score of less than 3 (i.e. at most
only slight disability from the index stroke, without
the need for assistance in daily affairs).
The following patients were excluded from the
study: those with a modified Rankin scale 3, with
evidence of potential alternative sources of emboli,
such as chronic atrial fibrillation or malformation of
the circle of Willis, either with lacunar infarct
(LACS, Lacunar Syndromes) or infarct in the vertebro-
basilar territory (POCS, Posterior Circulation Syn-
dromes), with images suggesting the presence of
a thrombus in the common or internal carotid artery
(string sign) and/or slow flow during contrast injec-
tion into the carotid axis.The study was approved by the Ethics Committee
and informed consent was obtained from all potential
study candidates prior to any procedure.
Baseline evaluation involved medical history, neu-
rological history, carotid duplex imaging, CT scan
and blood, serum and urine collections to detect
inflammatory biomarkers. A complete neurological
examination (modified Rankin Score,13 NIH Stroke
Scale e NIHSS14) was performed for each patient
pre-procedure, post-procedure, at discharge and at
30 days follow-up.
In order to evaluate the outcome of revasculariza-
tion, the patient sample was divided into clinically
improved (decrease on NIHSS 2), those unim-
proved (unchanged NIHSS or decrease on
NIHSS< 2), and those who were impaired (increase
on NIHSS).
A critical event committee composed of two neu-
rologists evaluated the neurological history at the dif-
ferent time intervals of the study and judged any
neurological adverse events.
Target lesion morphology with respect to ulcera-
tion, calcification and eccentricity was assessed by ul-
trasound and intra-operative angiography. A lesion
comprising 02 craters of 03 mm in depth or with
poorly defined edges and a hazy appearance was de-
fined as ulcerated, while a radiopaque area under
fluoroscopy was defined as calcified.
The stenting procedure was performed within 24e
48 hrs of the last attack in patients with TIA and be-
tween 14 and 30 days in patients with stroke, in order
to obtain the stabilization of the cerebral ischemic
lesion.
Prior to surgery all patients received 100e300 mg/
d of aspirin for at least 2 days prior to the operation
and either 75 mg of Clopidogrel for at least 24 hours
prior to the operation, or 300 mg of Clopidogrel on
the day of the surgery, at least 4 hours before com-
mencing the procedure. Heparin was administered
during the procedure at a dose of 5,000 IUs or similar,
so that an ACT> 250 sec was maintained throughout
the operation. Following surgery, all patients were
given 75 mg/d of Clopidogrel for a period of 1 month,
and 100 mg/d of aspirin indefinitely.
CAS was performed according to each unit’s exist-
ing standards of care. The vascular system was ac-
cessed via the femoral artery. Angiography of the
diseased carotid arterywas performed to confirm eligi-
bility criteria. An appropriate guide catheter or long
sheath was advanced over the guidewire to engage
the ostium of the diseased carotid artery. The guide-
wire with the filter was gently advanced across and
through the lesion and the filter was then positioned
in the distal segment of the internal carotid artery. IfEur J Vasc Endovasc Surg Vol 35, June 2008
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dilatation was performed. A stent of appropriate size
and length, according to the investigator’s discretion,
was then placed at the lesion site. A post-dilatation bal-
loon was carefully advanced until it was positioned
within the stent and then dilated to pressures sufficient
only to appropriately expand the stent. Angiography
of the stented segment was then repeated to ensure
the adequacy of stent deployment, lesion dilatation,
and distal flow.
The histo-morphometric analysis of plaque debris
was performed on each of the filters used. After re-
moval, filters were immediately fixed in 10% buffered
formalin and sent to the external histology core labo-
ratory for histological and cytological analysis. The in-
vestigators who performed the histological and
cytological assessment were unaware of the angio-
graphic and procedural results. Morphological identi-
fication of particles was done at 100 and 200-fold
magnification according to the following criteria: (1)
a particle was identified as a thrombus fragment if it
appeared to be a conglomerate of erythrocytes with
embedded strands of fibrin, and if the structure of sin-
gle erythrocytes could not be discerned; (2) a particle
was identified as a plaque fragment if it was a con-
glomerate of erythrocytes with embedded strands of
fibrin and localized structures corresponding to cho-
lesterol clefts, with the contour either serrated or
smooth but clearly different from a fissure. Lipid-
laden foam cells confirmed the diagnosis of a plaque;
(3) a particle was defined as an intima fragment if it
consisted of small pieces of collagen fibers covered
by endothelial cells or attached to plaque fragments.
These structures could be embedded in fibrin or
thrombus fragments, and foam cells could also be
included.
The carotid plaque vulnerability markers studied
were: pregnancy-associated protein A (PAPP-A),
high sensitivity C-reactive protein (hsCRP), Interleu-
kin 6 (IL-6), Interleukin 8 (IL-8), proteolytic enzyme
metalloproteinases (MMP2 and MMP9), tumour ne-
crosis factor (TNF ) and CD40 ligand (CD40L). These
vulnerability markers were evaluated prior to stent-
ing, immediately afterwards and at the 30 day
follow-up.
Blood was taken by venipuncture, placed in an
EDTA-free tube and centrifuged within 30 minutes
of collection at 3000 g  20 min, then the serum was
carefully separated from blood corpuscolate elements.
The serum was stored at 20 for core laboratory de-
termination of vulnerability biomarkers. Urine testing
was only done for PAPP-A levels: urine was collected
in a plastic vial (10 cc) and stored at 20 until ready
to be sent to the core laboratory for measurements. AtEur J Vasc Endovasc Surg Vol 35, June 2008the core laboratory serum and urinary PAPP-A levels
were determined by means of a biotinetyramidee
amplified enzyme immunoassay with a detection
limit of 0.03 m IU per litre and intraassay and interas-
say coefficients of variation of 10 percent and 15 per-
cent, respectively. PAPP-A polyclonal antibodies were
used for capture and a combination of monoclonal
antibodies was used for detection. A highly sensitive
latex particleeenhanced immunoturbidimetric assay
was used to quantify the level of high sensitivity
C-reactive protein.
Other serumbiomarkers (IL-6, IL-8,CD-40L,MMP-2,
MMP-9, TNF-alpha) were measured by enzyme-linked
immunosorbent assay (ELISA), using commercially
available immunoradiometric kits (Pantec, Turin, Italy).Statistical analysis
Categorical data were presented as absolute frequen-
cies and percent values. Quantitative measurements
were expressed as mean SD. Laboratory parameters
assessed at the beginning and at the end of the observa-
tion period were evaluated by parametric (Student’s t
test for paired data) or non parametric (Wilcoxon’s
test for paired data) methods. Comparison between
biomarkers levels at different study intervals was per-
formed by one-way repeated measures analysis of
variance (ANOVA) for parametric parameters. A
p value 0.05 was considered statistically significant
(statistical package: BMDPNew System 2.0e by Statis-
tical Solutions Ltd, Cork e Ireland).Results
Of the 57 patients enrolled, 42.1% (n¼ 24) had first ep-
isode or recurrent TIA, 57.9% (n¼ 33) had minor
stroke. The demographic characteristics are shown
in Table 1.
The target lesion stenosis was 75.9 11.6%. Lesion
characteristics are shown in Table 2.
Successful stent implantation was achieved in all
cases (100%). An Acculink stent was implanted in
96.5% of patients and a different type of stent (Carotid
Wallstent e Boston Scientific Corp, Natick, MA, USA)
was implanted in the other 2 patients (3.5%).
No intra-procedural neurological complications oc-
curred, while the minor complications that occurred
during the procedure were ICA vasospasm in 14%
of cases (n¼ 8) and severe hypertension in one case
(1.7%). Procedural success, defined as absence of
new cerebrovascular events at discharge (including
major stroke, minor stroke, or TIA), was assessed at
96.5%.
Table 1. Main baseline demographic characteristics and risk
factors profiles
(n¼ 57)
Age [Years (mean S.D.); range (MineMax)] 76.7 8.0 57e93
Male (n; %) 37 64.9
Diabetes Total (n; %) 13 22.8
Diabetes Non ID (n; %) 10 17.5
Hypertension (n; %) 49 86.0
Hypercholesterolemia (n; %) 15 26.3
HDL< 35 (n; %) 24 42.1
Hypertrigliceridemia (n; %) 7 12.3
Coronary artery disease (CAD) (n; %) 13 22.8
Previous MI (n; %) 8 14.0
Previous PTCA (n; %) 4 7.0
Previous CABG (n; %) 5 8.8
Family History for CAD (n; %) 15 26.3
Peripheral artery disease (n; %) 3 5.3
Renal Insufficiency (BUN> 20 mg/dl) (n; %) 6 10.5
ID: insulin dependent; HDL: high density lipoprotein; MI: myocardial
infarct; PTCA: percutaneous transluminal coronary angioplasty;
CABG: coronary artery bypass graft; BUN: blood urea nitrogen.
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rological event (TIA, 3.5%). Other non neurological ad-
verse events were 1 persistent bradicardia (1.7%), 1
patient with non-Q wave AMI (1.7%) and 1 with renal
insufficiency (1.7%).
At 1 month total neurological adverse events in-
cluded 1 death (1.7%) and 2 TIAs (3.5%). The sudden
death that occurred during the 30-day follow-up pe-
riod was probably due to a myocardial infarction.
The NIH/Rankin Score at the different study inter-
vals is shown in Fig. 1. No patients presenting with
minor stroke experienced a worsening of the neuro-
logical deficit at hospital discharge. The postoperative
NIHSS score at hospital discharge showed that in
50.9% (29/57) of patients the neurologic deficit re-
mained unchanged (decrease in NIHSS< 2) and in
28/57 (49.1%) the NIHSS score improved (decrease
in NIHSS 2). At 1 month 32/56 patients (57.1%) ex-
perienced an improvement in their initial neurologicTable 2. Lesion characteristics
(n¼ 57)
Hyperechoic lesions (n; %) 30 52.6
Hypoechoic lesions (n; %) 27 47.4
Angiographic ICA stenosis in %
(Mean SD; Range)
75.9 11.6 60e99
Ulcerated lesion (n; %) 7 12.2
Calcific lesion (n; %) 16 28.0
Eccentric lesion (n; %) 15 26.3
CCA involvement (n; %) 24 42
ECA involvement (n; %) 14 25
Angiographic Controlateral ICA
stenosis in % (Mean SD; Range)
40.0 34.4 0e100
ICA: internal carotid artery; CCA: common carotid artery; ECA: external
carotid artery.deficit, while in 42.9 % of patients the deficit remained
stable ( p> 0.05 in the neurological changes at differ-
ent study intervals).
The data concerning plaque vulnerability bio-
markers are shown in Figs. 2e4 (serum markers)
and Table 3 (urinary marker). P-values, statistical sig-
nificance and confidence intervals are indicated only
in the case of significance during the different time
intervals of the study: Pre-procedure (Pre), Post-
procedure (Post) and 30 day Follow-up (FU).
Vulnerability markers, in particular those reflecting
an active systemic inflammatory process as PAPP-A,
hs-CR, and inflammatory cytokines such as IL-6 and
IL-8, were significantly elevated at the time of enrol-
ment, increased after stenting and decreased after 30
days. A remarkable variation was noted for the
PAPP-A level, which decreased from 15.1 m IU/L af-
ter stenting to 6.9 m IU/L at 30 days, p< 0.01 CI
(95% confidence interval) 1.8e15.3; for hs-CRP, which
decreased from 23.2 mg/L after stenting to 9.7 mg/L
at 30 days, p< 0.01 95% CI 6.7e19.9; and for IL-6,
which decreased from 13.5 pg/ml after stenting to
7.4 pg/ml at 30 days, p< 0.01 95% CI 3.6e9.1.
The data concerning histopathologic evaluation of
plaque debris collected within the filters are summa-
rized in Table 4.
Discussion
Effective and early management of patients with
acute symptoms due to carotid stenosis is still the sub-
ject of debate. The inability to predict who is at higher
early risk of a recurrent stroke after a cerebrovascular
event (TIA or stroke) may explain the variation in
management of acute stroke comparing physician to
physician and institution to institution.
CEA has traditionally been delayed for 4 to 8 weeks
because of fear of hemorrhagic transformation of the
ischemic infarct. However, this disapproval of early
treatment after an acute stroke is inappropriate. Roth-
well et al1 have recently analyzed pooled data from
the European Carotid Surgery Trial and North Amer-
ican Symptomatic Carotid Endarterectomy Trial (a to-
tal of 5893 patients). The analysis of long-term stroke
prevention (per 1000 CEAs at 5 years) in relation to
the delay in surgery clearly showed that benefit
from surgery decreased rapidly with time elapsed
since the last neurological symptoms. Profit from end-
arterectomy seems to depend not only on the degree
of carotid stenosis, but also on delay in surgery after
the presenting event, and the conclusion was that
the procedure should ideally be done within 2 weeks
of the patient’s last symptoms. The same author in
2007 has reported a prospective study15 that showsEur J Vasc Endovasc Surg Vol 35, June 2008
Fig. 1. Rankin Score/NIH at different study intervals.
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all patients presenting with TIA or minor stroke can
prevent about 80% of early recurrent stroke.
In a prospective study of patients presenting with
acute symptomatic high-grade internal carotid artery
stenosis, the Oxford Vascular Study Group16 recently
observed that for patients with TIA the 7 day, 30 day
and 3 month risks of stroke were 8%, 12% and 17% re-
spectively, while for patients presenting with minor
stroke (NIH stroke score< 3) parallel data were 12%,
15% and 19%. These data suggest that acute stroke or
TIA be considered as medical emergencies that require
rapid evaluation and rapid targeting of treatment. The
reported stroke risks highlight how early removal of
the carotid plaque that is considered to be the embolic
source could be crucial in stroke prevention.
An Italian multicenter study e Surgical Treatment
of Acute Cerebral Ischemia (STACI)17 e has recently
shown that patients whose neuroimaging studies doc-
ument a recent, limited cerebral infarction in the early
hours after a stroke can safely undergo very early
CEA (1.5 days after the stroke). This study underlines
that if patients are strictly selected for early CEA after
an acute stroke, early surgery incurs similar risks to
elective surgery.Fig. 2. PAPP-A, hs-CRP and CD-40L sero
Eur J Vasc Endovasc Surg Vol 35, June 2008The SPREAD guidelines18 also clearly state that ca-
rotid surgery is recommended as early as possible e
within 2 weeks of the event e for patients with TIA,
minor stroke or stabilized neurological deficit with
normal CT scanning or minimal lesions (Grade A rec-
ommendation); while early carotid endarterectomy is
not recommended for patients with disabling stroke
or large infarction and/or brain oedema on CT scan-
ning (Grade C recommendation).
With growing experience in endovascular treat-
ment, CAS has been proposed as an alternative to
CEA, but data regarding the outcome of patients
with acute stroke undergoing urgent endovascular
surgery are still scarce.
The main concern about CAS in urgent cases is that
while with CEA the plaque is completely removed, af-
ter stenting it is only remodelled and its stabilization
is essential to avoid later embolic events.
Our prospective registry was designed not only to
demonstrate the safety and the efficacy of early CAS
after TIA (within 24e48 hours) or minor stroke
(within 14e28 days), but also to investigate the role
of the stent as a plaque stabilizer by analysing the be-
haviour of vulnerability biomarkers during the post-
operative period.logic levels at different time intervals.
Fig. 3. IL-6, IL-8 and TNF-alpha serologic levels at different
time intervals.
Table 3. Urine Plaque vulnerability biomarkers at different time









Pre-procedure 1.02 0.9 1.01 0.8 1.02 1.02
Post-procedure 1.21 0.86 1.22 0.78 1.21 0.93
p-value >.05 >.05 >.05
649Carotid Artery Stenting in Symptomatic PatientsWe demonstrated the safety of CAS in this series of
high risk/complex carotid cases enrolled and treated
soon after the onset of symptoms, as shown by the ab-
sence of neurological complications during the proce-
dure, a high procedural success rate, and the very low
rate of minor cerebrovascular events in the post-
operative period. Moreover, the high rate of signifi-
cant debris in the filter at histo-morphometric analysis
(54/57, 94.7%) may suggest the utility of a cerebral
protection device in such symptomatic cases.
The clinical outcome at 1 month of a 1.7% stroke/
mortality rate (1 non-neurological death) and 3.5%
rate for all neurological events (2 post-procedure
TIAs) are extremely satisfactory considering the very
high risk profile of the patient population.
In this study an open cell stent was used in 55 out
of 57 cases. Moreover, we are aware of the important
role of scaffolding of the emboligenic plaque by the
struts of the stent.19 Our purpose in the near future
is to further investigate the safety of CAS in symptom-
atic stroke patients using either a closed or an open
cell stent (Submarine II Registry).
Although the central role of inflammation in the
pathogenesis of atherosclerosis has been demonstra-
ted,20e28 the difficulty of noninvasively recognizingFig. 4. MMP-2 and MMP-9 serologic levels at different time
intervals.vulnerable plaques at early stages, and before the on-
set of an acute clinical event, still remains. Several
studies have shown that the histomorphologic com-
position of the atherosclerotic plaque,29e31 as well as
the degree of stenosis, is a major determinant for in-
creased risk of carotid plaque disruption and cerebral
embolization. In our Registry the vulnerability
markers, in particular those reflecting an active in-
flammatory infiltrate of the plaque, such as PAPP-A,
hs-CR, MMPs, and inflammatory cytokines, such as
IL-6 and IL-8, were significantly elevated in all pa-
tients at the time of enrolment. Several of these biolog-
ical markers have already been proposed to identify
both ruptured and eroded unstable coronary plaqu-
es.32e35 Sangiorgi et al36 have recently evaluated cellu-
lar PAPP-A expression in stable and unstable carotid
atherosclerotic plaques collected from patients under-
going surgical carotid endarterectomy. Their results
clearly correlate vulnerability biomarker levels with
histopathologic carotid plaque complexity: PAPP-A
was significantly higher in patients with vulnerable
and ruptured plaques (respectively 7.43 0.97 m IU/
L and 6.97 0.75 m IU/L) compared to patients with
stable plaques (4.02 0.18 m IU/L).
In our study the elevated serum PAPP-A values
(8.82 12.1 m IU/L) at the time of enrolment revealed
the systemic evidence of the presence of an inflamma-
tory state, possibly directly related to the carotid pla-
que in our series of symptomatic patients. This study
is the first to confirm that complex, high-risk plaques
are associated with an increase in biomarkers of vul-
nerability. Some of these markers, such as serum levels
of PAPP-A, Hs-CRp and IL-6, increased significantly
after the procedure and decreased at follow-up. Al-
thoughwe are aware that this trend is potentially influ-
enced by many other factors independently of the
placement of a carotid stent (such as medication, con-
trol of cardiovascular risk factors etc.), and may be
due to systemic effects, we believe that our study is
the first in the literature to show a possible correlation
between the behavior of some serummarkers and stent
implantation at the level of unstable carotid plaques.
However, the behavior of other biomarkers (serum
MMP, CD-40L, TNF-alpha, and urinary PAPP-A)
seemed to be of no value in our investigation.Eur J Vasc Endovasc Surg Vol 35, June 2008







19 (33,3%) 7 (29.2%) 12 (36.4%) 0.894*
Plaque fragment
(score 2)
18 (31,6%) 8 (33.3%) 10 (30.3%)
Intima fragment
(score 3)
17 (29,8%) 7 (29.2%) 10 (30.3%)
Absent 3 (5,3%) 2 (8.3%) 1 (3.0%)
Total 57 (100.0%) 24 (100.0%) 33 (100.0%)
* P-value concening Chi-square test on (Minor Stroke and TIA).
650 C. Setacci et al.On the basis of these considerations, our hypothesis
is that selected serum biomarkers, such as PAPP-A,
Hs-CRp and IL-6, could be related to the vulnerability
of symptomatic atherosclerotic plaques and that
carotid plaque stabilization by means of mechanical
intervention may also be linked to a reduction in the
expression of these vulnerability markers.
At this time further investigations are needed to
verify our hypothesis and to validate the utilization
of these vulnerability biomarkers as enhanced tools
in diagnostic pathways for symptomatic and asymp-
tomatic patients with carotid atherosclerotic disease.
At present, sophisticated imaging techniques such
as pixel density analysis and elastography at Duplex
examination,37,38 magnetic resonance imaging for tis-
sue characterization,39 or local temperature probes40,41
all hold promise for the non-invasive identification of
vulnerable plaques and the detection of silent
atheroma.
In conclusion, our study demonstrated that early
treatment with protected carotid stenting is both feasi-
ble and safe in selected patients with first episode or re-
current TIA or minor stroke. This preliminary study in
a limited series of patients revealed that anurgent endo-
vascular approach has a satisfactory outcome consider-
ing the very high risk profile of the patient population.
The time course of some serologic markers may be
of great interest in the study of the behaviour of unsta-
ble carotid plaques following stent implantation, and
could merit the attention of further studies.
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